Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors

Breast Cancer Clinical Trial

Official title:

Breast Cancer Prevention Using Synergistic Prostaglandin Inhibitors (The Vitamin D/Celecoxib Study)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01425476
• Other study ID #: 200806
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: April 26, 2011
• Last updated: August 8, 2017
• Start date: July 2008
• Est. completion date: November 2016

Study information

• Verified date: August 2017
• Source: Hartford Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a biomarker study with the goal of measuring changes in proteins and gene methylation. This study is not intended for use in diagnosing, mitigating, treating, curing, or preventing disease.

The purpose of this study is to determine if Vitamin D (cholecalciferol) alone and in combination with celecoxib (Celebrex, a non-steroidal anti-inflammatory drug, or NSAID), to decrease breast cancer risk by their effect on certain biological indicators (biomarkers) of breast cancer risk (called PGE2, COX-2, and 15-PGDH) and cell changes in the breast.

Description:

This is a biomarker study with the goal of measuring changes in protein and RNA expression. This study is not intended for use in diagnosing, mitigating, treating, curing, or preventing disease.

66 women at high risk for breast cancer (gail risk >/= 1.66% for 5 year risk, or personal or family history)will be recruited and enrolled. 22 women will be randomized into each arm, with anticipation of 2 women in each group will not be evaluable, leaving 20 in each group for evaluation.

A combination of vitamin D and celecoxib act synergistically to decrease breast cancer risk by decreasing cell proliferation in the mammary epithelium through their action on prostaglandin synthesis and metabolism.

Specific Aims:

In women at increased breast cancer risk, determine the effect of vitamin D, with or without celecoxib, on

1. PG synthesis and metabolism, through the measurement of 15-PGDH, COX-2, and PGE2 in the breast

Rationale: 1,25(OH)2D, the active form of vitamin D, has been shown in vitro to decrease PGE2 both by interfering with its production and by increasing its breakdown, leading to lower cell proliferation. Celecoxib potentiated the antiproliferative effect, allowing a much lower dose of each agent when used in combination than in isolation.

2. Proliferative activity in the breast, as measured by Mammary Ductoscopy (MD) cell morphology

Rationale: Both MD and Nipple Aspirate Fluid (NAF) contain ductal epithelial cells, but MD samples contain more cells for cytologic review than NAF. Findings on MD cytology correlate with likelihood of breast cancer (2), NAF cytology relates to breast cancer risk and improves risk stratification (3), and bioactive food components can alter NAF cytology (4).

3. Circulating levels of 25(OH)D, 1,25(OH)2D, and celecoxib, and determine if the levels of these compounds correlate with response to markers of PG synthesis and metabolism or cell proliferation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 45
• Est. completion date: November 2016
• Est. primary completion date: November 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Women 18 years of age or older

• Increased risk for breast cancer (demonstrated by strong family history [one 1st degree or two 2nd degree relatives], history of DCIS, IBC, or precancerous changes in breasts). OR Gail Model risk of developing IBC in a 5-year period of >1.66%

• Women with a history of breast cancer, must be free of disease and finished with treatment

• ECOG Performance Status score 0-1

• Premenopausal women must not be pregnant.

Exclusion Criteria:

• History of bilateral mastectomy, or bilateral breast irradiation

• Significant medical or psychiatric problems making the participant a poor candidate

• Evidence of excess use of narcotics or drug dependency

• Have been pregnant and lactating in the past 2 years

• Significant history of peptic ulcer disease or upper gastrointestinal bleeding

• History of severe congestive heart failure that requires hospitalization or intervention

• History of asthma requiring medication for treatment

• Allergy to sulfonamides or NSAID medications

• History of myocardial infarction or stroke

• Currently on Coumadin

• Currently on Tamoxifen (nolvadex),Evista (raloxifene), Femara (letrozole), Arimidex (anastrozole), or Aromasin (exemestane)

• Undergone prior subaeolar breast surgery

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Celecoxib
Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
• Placebo
Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
• Cholecalciferol
Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.

Locations

Country	Name	City	State
United States	University of North Dakota	Grand Forks	North Dakota

Sponsors (3)

Lead Sponsor	Collaborator
Hartford Hospital	United States Department of Defense, University of North Dakota

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PG synthesis and metabolism	This will be measured from both baseline and completion samples.; 1. PG synthesis and metabolism, through the measurement of 15-PGDH, COX-2, and PGE2 in the breast; Rationale: 1,25(OH)2D, the active form of vitamin D, has been shown in vitro to decrease PGE2 both by interfering with its production and by increasing its breakdown, leading to lower cell proliferation. Celecoxib potentiated the antiproliferative effect, allowing a much lower dose of each agent when used in combination than in isolation.	approximately 30 days
Secondary	Proliferative activity in the breast, as measured by MD cell morphology	This will be measured from both baseline and completion samples.; 2. Proliferative activity in the breast, as measured by MD cell morphology; Rationale: Both MD and NAF contain ductal epithelial cells, but MD samples contain more cells for cytologic review than NAF. Findings on MD cytology correlate with likelihood of breast cancer, NAF cytology relates to breast cancer risk and improves risk stratification, and bioactive food components can alter NAF cytology.	approximately 30 days
Secondary	Circulating levels of 25(OH)D, 1,25(OH)2D, and celecoxib	This will be measured from both baseline and completion samples.; 3. Circulating levels of 25(OH)D, 1,25(OH)2D, and celecoxib, and determine if the levels of these compounds correlate with response to markers of PG synthesis and metabolism or cell proliferation.	approximately 30 days